**All Interactions with Stavudine (Zerit)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Stavudine** | **Effect on Drug Levels** | **Effect on Stavudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Atazanavir[122](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#122)  (ATV)(Reyataz) | 400 mg x 1 | also dosed with didanosine | Atazanavir AUC: decreased 87%; Cmax: decreased 89% | Not studied | Decreased atazanavir effects | - | Dose adjustment not established |
| Chlorpropamide[469](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#469)  (others)(Diabinese) | 250 mg x 1 | 40 mg QD x 1 | Chlorpropamide AUC: decreased 45%; Cmax: decreased 35% | - | Potentially increased serum glucose concentrations | - | Consider alternative agent  *Alternative Agents*:  **Glyburide, glipizide, metformin** |
| Clarithromycin[275](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#275)  (Biaxin) | 500 mg BID | 40 mg BID | - | Stavudine AUC: no significant change; Cmax: decreased 15%; Cmin: decreased 41% | - | - | No dose adjustment necessary |
| Didanosine[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#19)  (ddI)(Videx) | 100 mg (buffered formulation) x 4 days | 40 mg Q12H x 4 days | No significant change | Stavudine AUC: no significant change; Cmax: increased 17% | - | - | No dose adjustment necessary |
| Didanosine[86](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#86),[87](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#87)  (ddI)(Videx) | 100 mg Q12H x 9 doses | 40 mg Q12H x 9 doses | No significant change | No significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Stavudine** | **Effect on Drug Levels** | **Effect on Stavudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Emtricitabine[125](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#125)  (FTC)(Emtriva) | 200 mg x 1 dose | 40 mg x 1 dose | No significant change | No significant change | - | - | No dose adjustment necessary |
| Fluconazole[275](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#275)  (Diflucan)(Diflucan) | 200 mg QD | 40 mg BID | - | Stavudine AUC: no significant change; Cmax: no significant change; Cmin: increased 25% | - | - | No dose adjustment necessary |
| Ganciclovir[234](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#234)  (Cytovene) | 1000 mg Q8H (oral) | 40 mg Q12H | No significant change | No significant change | - | - | No dose adjustment necessary |
| Indinavir[105](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#105)  (IDV)(Crixivan) | 800 mg on days 1 and 2, 800 mg indinavir with 200 mg ritonavir BID on days 3-17 | 40 mg BID | Not studied | Stavudine AUC: increased 24% (with indinavir and ritonavir); AUC: increased 14% (with indinavir alone); Cmax: no significant effect | - | - | No dose adjustment necessary |
| Indinavir[16](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#16)  (IDV)(Crixivan) | 800 mg Q8H x 1 week | 40 mg Q12H x 1 week | No significant change | Stavudine AUC: increased 25% | - | - | No dose adjustment necessary |
| Lamivudine[86](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#86)  (3TC)(Epivir) | - | - | No significant change | No significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Stavudine** | **Effect on Drug Levels** | **Effect on Stavudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Methadone[203](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#203)  (Dolophine)(Dolophine) | - | 40 mg BID | - | Stavudine AUC: decreased 23%; Cmax: decreased 44% | - | Decreased stavudine bioavailability | No dose adjustment necessary |
| Nelfinavir[86](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#86)  (NFV)(Viracept) | - | - | - | - | - | - | No dose adjustment necessary |
| Nelfinavir[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#24)  (NFV)(Viracept) | 750 mg TID x 56 days | 30 mg to 40 mg BID x 56 days | Not studied | No significant change | - | - | No dose adjustment necessary |
| Ribavirin[236](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#236)  (Rebetol, Virazole) | 800 mg QD | 40 mg BID | - | No significant change | - | - | No dose adjustment necessary |
| Rifabutin[275](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#275)  (Mycobutin)(Mycobutin) | 300 mg QD | 40 mg BID | - | Stavudine AUC: no significant change; Cmax: decreased 30%; Cmin: increased 105% | - | - | No dose adjustment necessary |
| Tenofovir disoproxil fumarate[136](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#136)  (TDF)(Viread) | 300 mg QD on days 2-9 | 100 mg XR QD on days 1 and 9 | No significant change | - | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Stavudine** | **Effect on Drug Levels** | **Effect on Stavudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Tenofovir disoproxil fumarate[12](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#12)  (TDF)(Viread) | 300 mg QD x 7 days | 100 mg extended release x 1 dose | Not studied | No significant change | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#154)  (TPV)(Aptivus) | 1250 mg BID with 200 mg ritonavir BID x 23 doses | 30 mg BID x 43 doses | - | Stavudine Cmax: decreased 26% | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#154)  (TPV)(Aptivus) | 250 mg BID with 200 mg ritonavir BID | 40 mg BID | - | No significant change | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#154)  (TPV)(Aptivus) | 750 mg BID with 100 mg ritonavir BID | 40 mg BID | - | Stavudine Cmax: decreased 24% | - | - | No dose adjustment necessary |
| Zidovudine[86](http://arv.ucsf.edu/insite?page=ar-00-02&param=13&post=4#86)  (AZT, ZDV)(Retrovir) | - | - | - | - | Decreased stavudine effects | Competitive inhibition of intracellular phosphorylation of stavudine | Do not coadminister |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 12: | Kaul S, Bassi K, Damle B, et al. Lack of interaction between stavudine extended-release formulation and tenofovir disoproxil fumarate [abstract #534]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts. |
| 16: | Crixivan [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; Oct 2005. |
| 19: | Videx [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2003. |
| 24: | Viracept [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept 2004. |
| 84: | Videx EC [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Oct 2005. |
| 86: | Zerit [package insert]. Princeton, NJ: Bristol-Myers Squibb Immunology; Sept 2005. |
| 87: | Seifert RD, Stewart MB, Sramek JJ. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol 1994;38:405-10. |
| 105: | Kaul S, Agarwala S, Hess, H. et al. The effect of coadministration of indinavir (IDV) and ritonavir (RTV) on the pharmacokinetics of stavudine (d4T). [abstract #A-1825]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois. |
| 122: | Omara E et al. BMS-232632: A summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects [abstract #504]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco, California. |
| 125: | Emtriva [package insert]. Foster City, CA: Gilead Sciences, Inc.; Sept 2005. |
| 136: | Kaul S, Bassi K, Damle B, et al. Stavudine extended release formulation and tenofovir disoproxil fumarate: lack of a pharmacokinetic drug interaction [abstract #602]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California. |
| 154: | Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005. |
| 203: | Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 2000;24:241-8. |
| 234: | Jung D, Abdel Hameed MH, Teitelbaum P, et al. The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients. J Clin Pharmacol 1999;39:505-12. |
| 236: | Gries J-M, Torriani FJ, Rodriguez-Torres M, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV/HIV co-infection: final results of a randomized clinical study [abstract #136LB]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California. |
| 275: | Piscitelli SC, Kelly G, Walker RE, et al. A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodefieciency virus-infected patients. Antimicrob Agents Chemother 1999;43:647-50. |
| 469: | Bakare-Odunola MT, Enemaili I, Garba M, et al. The influence of lamivudine, stavudine and nevirapine on the pharmacokinetics of chlorpropamide in human subjects. Eur J Drug Metab Pharmacokinet 2008; 33: 165-71. |